MedTrace Logo

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2024-05-03

Study results available
· View outcomes & findings →

Summary

Response Rate

Conditions

Interventions

DRUG

Azacitidine

DRUG

Entinostat

DRUG

Nivolumab

DRUG

CC-486 300

Sponsors & Collaborators

  • Rising Tide Foundation

    collaborator OTHER

  • Stand Up To Cancer

    collaborator OTHER

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Celgene

    collaborator INDUSTRY

  • Syndax Pharmaceuticals

    collaborator INDUSTRY

  • Rhone-Poulenc Rorer

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Julie Brahmer, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-06
Primary Completion
2023-04-04
Completion
2023-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928576 on ClinicalTrials.gov